Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

China, licensing agreement with 3SBio, granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

3SBio also launched Cipterbin (inetetamab) in 2020 and was covered under the National Reimbursement Drug List, or NRDL, the same year. This is an analog of Roche’s anti-HER2 mAb Herceptin.

3SBio has good financial health. As of 2019, total debt was CNY 2.8 billion, net debt was CNY 700 million, and net debt to equity was a mere 7%. We project 2020 operating cash flow at CNY 1.5 ...

3SBio Inc. detailed financials by Barron's. View 1530 business summary and company performance, for a clear financial breakdown.

The positions in the table below reflect the 3SBio's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...

3SBio: Insider buying and selling updated today. Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a ...

Under the proposal, CITIC has provided "equity commitment", 3SBio said. 3SBio's ADSs shares were trading at $14.67 on Friday on the Nasdaq. The stock rose to a high of $15.00 earlier in the session.